CALL US: 1-800-392-1353 OR Request a Scheduled Call Below

Care Oncology US

Menu

Request Call
COC Quick Start
News
- Media
COC Glioblastoma Treatment
- Glioblastoma Testimonial – After 12 Months “no evidence of recurrence” – COC Protocol
COC – Select Cancer Types
FAQ
- For Providers
Team
- Nurse Team
Register Now – Care Oncology Webinar
Why we do what we do
- Care Oncology – Patient Experiences
How we do what we do
- Medical Records
How It Works

Home » Protected: Care Oncology – Nurse Team Webinar Series

This content is password protected. To view it please enter your password below:

Password:

COC Protocol is offered as an adjunctive therapy for conventional cancer therapies. COC Protocol may enhance the efficacy of conventional cancer therapies. It is not intended to replace conventional cancer therapies.

"Patient survivability doubled." Statement is based on the results of a 95-patient cohort phase-3 clinical trial of COC Protocol with patients diagnosed with glioblastoma multiforme. Additional results from the clinical trial for glioblastoma and other cancer types will be released as they become available. The COC study is filed in the UK under the title: Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer (METRICS) ClinicalTrials.gov Identifier: NCT02201381

"May halve the risk of dying from cancer" Statement is quoted from findings that were presented during the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. Context: Statin use was associated with a 22% reduction in deaths from various cancer types in women and a 55% reduction in deaths from bone/connective tissue cancers. The study in men looked at statin use together with metformin and found a 40% reduction in prostate cancer mortality, with the effect more pronounced in men with obesity/metabolic syndrome.

"COC Protocol" and "Care Oncology" and the "flame" icon are registered trademarks by Care Oncology LLC. COC Protocol is protected by United States patent US9622982B2 and by various additional international patents.